Optimizing Tamoxifen Dose for Premenopausal Breast Cancer Prevention
Background
Breast cancer remains a significant health concern, and Tamoxifen is an established medication used to reduce its incidence in high-risk women. While effective, the standard dose can be associated with side effects, potentially leading to compliance issues. This Phase II single-arm trial aims to identify a refined, potentially lower, optimal dose of Tamoxifen for premenopausal women to maximize benefits while minimizing adverse effects.
Study Design
Results
As this is a recruiting Phase II trial, specific findings are not yet available. However, the study aims to determine the optimal Tamoxifen dose that demonstrates significant breast cancer risk reduction while maintaining an acceptable safety profile in premenopausal women. Researchers will evaluate various biomarkers and clinical endpoints to assess the drug's impact on breast tissue changes and systemic side effects, such as hot flashes or endometrial thickening. The study anticipates providing data on how different doses affect hormonal markers and cellular proliferation within breast tissue, guiding future clinical decisions. > The primary objective is to identify a Tamoxifen dose that achieves a favorable balance between efficacy in preventing breast cancer and tolerability, potentially leading to a lower incidence of adverse events compared to standard dosing.
Why It Matters
This research is crucial because it could lead to a more personalized and tolerable preventative strategy for breast cancer in premenopausal women. By refining the Tamoxifen dose, the study hopes to improve patient adherence and overall quality of life, making prevention more accessible and sustainable. If successful, the findings could establish a new standard of care for breast cancer risk reduction, potentially moving to larger Phase III trials to confirm efficacy and safety in a broader population.